{"links":{"html":"https://www.erudio.com/reports/chimera-nct06155279","json":"https://www.erudio.com/reports/chimera-nct06155279.json","markdown":"https://www.erudio.com/reports/chimera-nct06155279.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"chimera-06155279"}},"request":"https://www.erudio.com/contact?report=chimera-06155279"},"offer":{"cited_commentary_sources":6,"verified_hcp_statements":22,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":0,"optional":true,"price_per_verified_person_usd":15,"price_usd":null,"product":null,"terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12"],"report":"chimera-nct06155279"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=chimera-06155279","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/chimera-nct06155279","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T01:23:06.393321Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the report description. The trial's name is spelled as its investigators write it, “CHIMERA” (NCT06155279), outside quotations (was “Chimera”, “ChimeraX”)."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":7,"no_commentary_found":1},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Primary endpoint - To evaluate the activity of neo-adjuvant treatment by the determination of pathological complete response rate (pCR)"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":2,"title":"Secondary endpoints"},{"claim_count":2,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":5,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":4,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":2,"coverage":"discussed","id":"A1","source_count":2,"title":"Residual-tumor heterogeneity and translational patient selection"},{"claim_count":1,"coverage":"discussed","id":"A2","source_count":1,"title":"Public-facing enthusiasm and the open question of outcome benefit"}],"counts":{"cited_sources":7,"claims_by_expression_type":{"interpretation":6,"opinion":1,"primary_context":7,"question":1,"restatement":6,"uncertainty":1},"claims_by_kind":{"protocol_statement":2,"source_observation":20},"clinician_statements":0,"evidence_units":12,"findings":4,"organisational_accounts":3,"people_cited":1,"people_identity_verified":0,"people_total":1,"screened_sources":69,"verified_claims":22},"findings_index":[{"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":7,"views":4},"has_counterview":false,"limitations":3,"links":{"context":2,"support":12},"ma_question":true,"named_voices":1,"passages":4,"sources":4,"sources_by_kind":{"commentary":1,"media":2,"registry":1}},"title":"Interest in MPR does not reverse the negative primary endpoint"},{"id":"F2","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":3},"has_counterview":false,"limitations":2,"links":{"context":1,"support":3},"ma_question":true,"named_voices":1,"passages":3,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Response heterogeneity leaves the benefiting population unresolved"},{"id":"F3","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":3},"has_counterview":false,"limitations":2,"links":{"context":1,"support":5},"ma_question":true,"named_voices":1,"passages":3,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Centralized surgery is a distinctive feature of a speaker's account"},{"id":"F4","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":0},"has_counterview":false,"limitations":2,"links":{"context":0,"support":1},"ma_question":false,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"A public-facing account expresses enthusiasm as a question, not a benefit claim"}],"medical_affairs_question":"How should the MPR signal be discussed without implying a positive primary endpoint or an identified benefiting subgroup?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Interest in MPR survives a negative primary endpoint"},{"id":"section-2","level":2,"title":"Heterogeneity is a reason for further patient-selection work"},{"id":"section-3","level":2,"title":"The surgical setting is part of the experience being presented"},{"id":"section-4","level":2,"title":"Public enthusiasm remains an unanswered outcome question"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":6}],"id":"T1","label":"Primary endpoint: Primary endpoint - To evaluate the activity of neo-adjuvant treatment by the determination of pathological complete response rate (pCR)"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F3","shared_claims":2}],"id":"T4","label":"The comparison"},{"findings":[],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":4}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T01:23:06.393321Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T01:33:04Z","record_hash":"a4598217b2cb4bbcd796f1edf48782ed6624f03873f32dec788d760e9d33888a","release_hash":"a3834a939da718c950197bb356142530b66783ff5095315fffca7abcd912cb15","report_id":"erudio-nct06155279","run_id":"b705470b-e018-41ce-8fd5-5525c302467b","schema_version":"5.0","slug":"chimera-06155279","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"CHIMERA asks whether pembrolizumab plus platinum–pemetrexed before surgery produces pathological complete responses in resectable epithelioid or biphasic pleural mesothelioma. Commentary comes from YouTube, a podcast and X posts, including an interviewee described in the sources as presenting CHIMERA and as a principal investigator. Discussion centers on that speaker’s interest in major pathological response despite a negative primary-endpoint assessment, and on the unresolved question of which patients might benefit from the regimen.","meta_description":"69 sources screened · 22 verified statements (0 from clinicians verified by NPI or staff page) from 7 sources · 4 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-31T01:33:04Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-31T02:18:08Z","summary":"Corrected to match the delivered report: the report description. The trial's name is spelled as its investigators write it, “CHIMERA” (NCT06155279), outside quotations (was “Chimera”, “ChimeraX”)."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":69},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 5 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","3 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The named clinical interpretation comes from a speaker. The video, podcast account and publisher summaries should not be counted as independent HCP agreement.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Some other videos considered for this edition lacked fully checked speaker-by-speaker transcripts, limiting coverage beyond the named account summarized here.","No separate full protocol, exact-trial results publication or exact regulatory label for the complete regimen was identified in the reviewed materials. Registry methods and interview reporting cannot resolve all result-denominator questions or establish regulatory status.","The podcast transcript contains an enrollment discrepancy, while the video account reports 41 enrolled patients. No reconciliation is available.","No substantive safety or tolerability assessment, survival interpretation or completed predictive patient-selection result was identified in the assessed statements. These absences are not evidence of safety, lack of survival benefit or absence of a benefiting subgroup."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":1,"regulatory":0,"x_thread":4,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":6,"methods":1},"count":7,"evidence_window":{"end":"2026-10-27","start":"2026-07-28"},"retrieval_snapshot":"2026-10-31T00:51:07.012253Z","timeline":[{"count":2,"week":"2026-W31"},{"count":2,"week":"2026-W38"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06155279:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06155279:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-3botkcmtgio7ah7eg4ogb7te-3m73qbnj3k226","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kh5lxshdhqlwegxzdbtgoni4-3lbs37iylno2x","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mt4db4uc626ds6iiilf56zy6-3lfnhfijt3s2e","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-oso4bdjawe5fc4otv22ue6xg-3kfseohrq6q2o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-oso4bdjawe5fc4otv22ue6xg-3lsgqksxyek2j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-rw2kfkoa7dvxmip5rm4nay7x-3lfwr6cvxp22h","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-rw2kfkoa7dvxmip5rm4nay7x-3lwgk6xpjys2i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-rz3r3btreilp2ez7spyi52ds-3lbzafrohsc2z","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-yoqbdkzhkjqz3vt4v4obfdqb-3l577xkns4t2x","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3mvb3vvi7lr23","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:072a4c","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:0f2c8e","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:1648c4","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:284bfe","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:535d91","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5423cb","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7168a4","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:784897","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a70b68","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:cb83d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1726586321311859087:4f3a6cae-22bd-4b83-ad90-8bc28f1d01e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1750872867212873910:f91a624c-cd45-4b38-8464-3da57a59220d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1804206391168536952:f2ec1133-8305-41d7-9088-02acb4b2c9ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1804263525868802503:95fbeba0-1f7a-4328-934d-cd954692fbf7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834238653838569765:92ec9dc9-f699-4cf8-8d95-f612114485b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1856534482716688730:1ca6e520-1d1b-4c78-95c4-61f02f1de18e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1867572494799897073:4da77733-9d2a-433d-a1a1-7b673225e04d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1899553008217653295:eee42232-95f2-4f8a-9f14-3bdb0ab986f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1907819027637924017:7142f224-9943-443e-9d3d-192a3718577d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928882671834247525:643c6e98-aecd-49ff-901e-9fb34a3382d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1947643161729241399:af7cfca9-1e64-420f-b591-5d979dee91de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1947665562311545266:0fb40b72-e682-4f75-a2e1-c724e3d5e6b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1954893037005636049:2ca001d7-e486-484c-b893-ce6bdb5c67ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1982876299703247344:05931d40-26aa-42b6-bba1-e05da0dde7eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1987081585133248784:c4a75e05-4275-4421-8914-77dc5e1434f1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1987347451783893025:6e471dde-944f-4c65-b3ac-fffd421ab1f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2036968723999764736:99ab06d1-a71b-4f9d-ac4a-5b949907e2dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049143004552696210:243f816d-9a7a-4487-b4bd-7525e36d9379","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2082005776919318981:10ae2a50-3602-49c7-b9e5-ad1cbd2447cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2082822174461567009:784105ed-89ae-40ee-8aa5-60a1b4edff6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092248988066136126:60072f59-2475-4d1e-8ea5-a39204f534bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098463197854347298:cf323fd0-6164-46a0-9705-1b5463c2f056","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106499861436829893:44f8cea1-9f2d-4fe2-9745-4f3bb090ca1c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108814865217307037:cbbb02fe-7417-48f3-8fc1-620d1a8ed366","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110305864410431977:e01665ad-ceb1-414a-8da0-26dfbbff9473","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111498936796254327:5c9e2f11-bc14-4cb5-a0ac-1f0d648cefeb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112838808400019862:1114437d-8bac-4f79-a6bd-12b428ac06e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114076988520460590:717cb5b3-bcb5-490f-87e9-3b7988b677c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114990556744925452:8c007195-9508-45d8-a713-c2082c51f066","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:0OD8IS39cPE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:1ePW-Z2Tfrc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:2JsPexTLPWM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:5gljJig7z5A","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:75xhYSJ2wO0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Az_6pas_Py4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:L3SHsuTMbV0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:NcwsgfHwWhw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:QzZGdgURG5k","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:UgcPJHW5MrQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:aSrIBEdlSOA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ajEPu2TwkaQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:hpT361cJKdM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:hxSxWPFaRhc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:k3WZEG-rAOU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:mp1uWB1iecY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:o3hMBvDFv_k","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:pHYW2fMXW-4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ykLYo_AY8qo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ysU4Ed28Chk","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":10,"linkedin_post":0,"other":0,"podcast":10,"publication":0,"registry":0,"regulatory":0,"x_thread":29,"x_video":0,"youtube":20},"by_evidence_role":{"commentary":69},"count":69,"evidence_window":{"end":"2026-10-27","start":"2023-11-20"},"retrieval_snapshot":"2026-10-31T00:51:10.742776Z","timeline":[{"count":1,"week":"2023-W47"},{"count":1,"week":"2023-W49"},{"count":1,"week":"2024-W02"},{"count":1,"week":"2024-W04"},{"count":1,"week":"2024-W07"},{"count":1,"week":"2024-W13"},{"count":1,"week":"2024-W17"},{"count":1,"week":"2024-W23"},{"count":2,"week":"2024-W25"},{"count":1,"week":"2024-W33"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2024-W39"},{"count":1,"week":"2024-W43"},{"count":1,"week":"2024-W46"},{"count":1,"week":"2024-W47"},{"count":1,"week":"2024-W48"},{"count":2,"week":"2024-W50"},{"count":2,"week":"2025-W03"},{"count":1,"week":"2025-W11"},{"count":1,"week":"2025-W12"},{"count":1,"week":"2025-W14"},{"count":2,"week":"2025-W15"},{"count":1,"week":"2025-W22"},{"count":1,"week":"2025-W23"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W25"},{"count":1,"week":"2025-W26"},{"count":2,"week":"2025-W30"},{"count":2,"week":"2025-W33"},{"count":2,"week":"2025-W40"},{"count":1,"week":"2025-W44"},{"count":2,"week":"2025-W45"},{"count":2,"week":"2025-W46"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W06"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W18"},{"count":2,"week":"2026-W26"},{"count":2,"week":"2026-W31"},{"count":2,"week":"2026-W33"},{"count":1,"week":"2026-W35"},{"count":2,"week":"2026-W37"},{"count":3,"week":"2026-W38"},{"count":1,"week":"2026-W40"},{"count":2,"week":"2026-W41"},{"count":2,"week":"2026-W42"},{"count":2,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":1}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: carboplatin/cisplatin - pemetrexed - pembrolizumab","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Pleural Mesothelioma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"CHIMERA","aliases":["CHIMERA","Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)","Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed as Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)"],"brief_title":"Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)","collaborators":["MSD Italia S.r.l."],"conditions":["Pleural Mesothelioma"],"display_condition":"resectable epithelioid and biphasic pleural mesothelioma","display_interventions":[["pembrolizumab","pemetrexed","platinum-based chemotherapy"]],"enrollment":{"count":41,"type":"ACTUAL"},"interventions":[{"name":"Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab","synonyms":["Keytruda"],"type":"DRUG"}],"nct_id":"NCT06155279","official_title":"Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed as Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2025-12-22","type":"ACTUAL"},"primary_endpoints":[{"description":"Pathological complete response defined as 0% residual viable tumor cells in the primary tumor and in sampled lymph nodes, following neoadjuvant treatment as assessed by central pathology assessment. Patients who are not evaluable per central pathology assessment (this includes patients with R2 margins) or who do not have a surgical specimen will be considered as non-pCR (eg, pathology assessments captured as \"non-evaluable\" or \"missing,\" as appropriate). Patients who received less than 2 cycles out of the planned 3 cycles of neoadjuvant therapy due to unacceptable toxicity will not be considered in the pCR evaluation.","measure":"Primary endpoint - To evaluate the activity of neo-adjuvant treatment by the determination of pathological complete response rate (pCR)","timeFrame":"Pathological complete response will be evaluated following neoadjuvant treatment and within 6 weeks after the last dose of study intervention."}],"registered_date":{"date":"2023-12-04","type":"ACTUAL"},"registry_last_updated":"2026-01-13","registry_url":"https://clinicaltrials.gov/study/NCT06155279","short_name":"CHIMERA","short_name_basis":"registry_acronym","sponsor":"Istituto Oncologico Veneto IRCCS","start_date":{"date":"2024-11-06","type":"ACTUAL"},"study_design":"interventional, na, single group, phase2","study_ids":[{"id":"IOV-Me-01-2023-CHIMERA","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}